InsiderPulseNo transactions found.
| Date | Member | Chamber | Type | Amount |
|---|---|---|---|---|
| 2026-03-03 | Gilbert Cisneros(D-CA31) | house | Purchase | $1,001 - $15,000 |
| 2026-02-10 | Gilbert Cisneros(D-CA31) | house | Purchase | $1,001 - $15,000 |
| 2025-11-12 | Gilbert Cisneros(D-CA31) | house | Sale | $1,001 - $15,000 |
| 2025-06-16 | Gilbert Cisneros(D-CA31) | house | Purchase | $1,001 - $15,000 |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total revenue | $9.7M-26.5% | $13.2M-30.5% | $18.9M-43.3% | $33.4M+67.9% | $19.9M |
| Intangible asset amortization - cost of revenue | $10.7M-7.7% | $11.6M-37.4% | $18.5M-4.2% | $19.3M | — |
| Total cost of revenue | $154.6M+4.7% | $147.6M+12.4% | $131.4M+8.7% | $120.9M | — |
| Gross profit | $362.5M+21.6% | $298.1M+29.8% | $229.7M+30.7% | $175.7M | — |
| Research and development | $70.8M+2.2% | $69.3M+20.9% | $57.3M+41.1% | $40.6M+36.1% | $29.8M |
| Selling and marketing | $100.2M+5.0% | $95.4M-6.0% | $101.5M+4.0% | $97.6M+22.2% | $79.8M |
| General and administrative | $110.8M+0.2% | $110.6M+28.3% | $86.2M+17.8% | $73.2M-27.8% | $101.4M |
| Impairment of assets | $20.5M+508.8% | $3.4M-95.1% | $68.3M | — | — |
| Total operating expenses | $304.8M+8.1% | $282.0M-10.6% | $315.5M+45.5% | $216.8M-28.1% | $301.4M |
| Income (loss) from operations | $57.8M+257.9% | $16.1M+118.8% | -$85.8M-108.8% | -$41.1M | — |
| Other income, net | $10.4M+8.6% | $9.6M+4.6% | $9.2M+97.3% | $4.7M+1732.3% | $254K |
| Income (loss) before income taxes | $68.2M+164.9% | $25.7M+133.6% | -$76.6M-110.3% | -$36.4M | — |
| Income tax provision (benefit) | $1.8M+15.1% | $1.6M+172.7% | -$2.2M-1760.2% | $133K | — |
| Net income (loss) | $66.4M+174.9% | $24.1M+132.4% | -$74.4M-103.5% | -$36.6M | — |
| Basic (in USD per share) | $840+162.5% | $320+131.4% | -$1K-100.0% | -$510 | — |
| Diluted (in USD per share) | $820+164.5% | $310+130.4% | -$1K-100.0% | -$510 | — |
| Basic (in shares) | $78.58B+2.7% | $76.48B+5.3% | $72.64B+1.5% | $71.55B | — |
| Diluted (in shares) | $80.57B+3.1% | $78.16B+7.6% | $72.64B+1.5% | $71.55B | — |
| Testing revenue | |||||
| Total revenue | $9.7M-26.5% | $13.2M-30.5% | $18.9M-43.3% | $33.4M+67.9% | $19.9M |
| Cost of revenue | $7.6M-38.8% | $12.4M-19.2% | $15.3M-16.9% | $18.4M+91.1% | $9.7M |
| Product revenue | |||||
| Total revenue | $9.7M-26.5% | $13.2M-30.5% | $18.9M-43.3% | $33.4M+67.9% | $19.9M |
| Cost of revenue | $7.6M-38.8% | $12.4M-19.2% | $15.3M-16.9% | $18.4M+91.1% | $9.7M |
| Biopharmaceutical and other revenue | |||||
| Total revenue | $9.7M-26.5% | $13.2M-30.5% | $18.9M-43.3% | $33.4M+67.9% | $19.9M |
| Cost of revenue | $7.6M-38.8% | $12.4M-19.2% | $15.3M-16.9% | $18.4M+91.1% | $9.7M |
| Intangible Asset Amortization | |||||
| Intangible asset amortization - operating expenses | $2.5M-24.6% | $3.3M+56.6% | $2.1M+1.2% | $2.1M | — |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Veracyte Announces New Data at AUA 2026 Highlighting the Power of the Decipher Portfolio to Advance Personalized Care in Urologic Cancers
Veracyte (VCYT) Recently Broke Out Above the 50-Day Moving Average
If You Invested $1000 in Veracyte a Decade Ago, This is How Much It'd Be Worth Now
Jefferies Initiates Coverage of Caris Life Sciences Inc. (CAI) With a Buy Rating